Telotristat ethyl is an investigational drug.
There have been 15 clinical trials for Telotristat ethyl.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.
The most common disease conditions in clinical trials are Neuroendocrine Tumors, Carcinoid Tumor, and Malignant Carcinoid Syndrome. The leading clinical trial sponsors are Lexicon Pharmaceuticals, TerSera Therapeutics LLC, and M.D. Anderson Cancer Center.
There are thirteen US patents protecting this investigational drug and one hundred and twenty-three international patents.